Quarter
Charts

Senti Biosciences, Inc.

SNTI

CIK 0001854270 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$22K
Gross Profit
$22K

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
10/100
  • Profitability
    0ROIC -347.9% (10% = solid, 20%+ = moat)
  • Liquidity
    58Current Ratio 1.67 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.00x (1.0+ = capital-efficient)
  • Growth
    0Insufficient data
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$196K
investment in PP&E
Stock-based comp (TTM)
$6M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$51M
everything owned
Total liabilities
$46M
everything owed
Stockholders' equity
$6M
shareholder claim

Recent performance · 20 quarters

Revenue
$22K
Net Income↑+37.2% +$11M
$-18M
Free Cash Flow↑+100.0% +$11K
$0
Operating Margin↓-12146.0pts
-12981.1%

Drill down

SNTI Sankey

See Senti Biosciences, Inc.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

SNTI Charts

20 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

SNTI Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics